JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 8, 2003; DOI: 10.1124/jpet.103.054775


0022-3565/03/3073-947-954$20.00
JPET 307:947-954, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.054775v1
307/3/947    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhao, G.-M.
Right arrow Articles by Szeto, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhao, G.-M.
Right arrow Articles by Szeto, H. H.

NEUROPHARMACOLOGY

Comparison of [Dmt1]DALDA and DAMGO in Binding and G Protein Activation at µ, {delta}, and {kappa} Opioid Receptors

Guo-Min Zhao, Xuanxuan Qian, Peter W. Schiller, and Hazel H. Szeto

Department of Pharmacology, Joan and Sanford I. Weill Medical College of Cornell University, New York, New York (G.-M.Z., X.Q., H.H.S.); and Laboratory of Chemical Biology and Peptide Research, Clinical Research Institute of Montreal, Montreal, Quebec, Canada (P.W.S.).

[Dmt1]DALDA (H-Dmt-D-Arg-Phe-Lys-NH2; Dmt = 2',6'-dimethyltyrosine) binds with high affinity and selectivity to the µ opioid receptor and is a surprisingly potent and long-acting analgesic, especially after intrathecal administration. In an attempt to better understand the unique pharmacological profile of [Dmt1]DALDA, we have prepared [3H][Dmt1]DALDA and compared its binding properties with that of [3H]DAMGO ([D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin). Kinetic studies revealed rapid association of [3H][Dmt1]DALDA when incubated with mouse brain membranes (K+1 = 0.155 nM–1 min–1). Dissociation of [3H][Dmt1]DALDA was also rapid (K–1 = 0.032 min–1) and indicated binding to a single site. [3H][Dmt1]DALDA binds with very high affinity to human µ opioid receptor (hMOR) (Kd = 0.199 nM), and Kd and Bmax were reduced by sodium but not Gpp(NH)p [guanosine 5'-({beta},{gamma}-imido)triphosphate]. Similar Kd values were obtained in brain and spinal cord tissues and SH-SY5Y cells. The hMOR:hDOR (human {delta} opioid receptor) selectivity of [Dmt1]DALDA (~10,000) is 8-fold higher than DAMGO. However, [Dmt1]DALDA is less selective than DAMGO against hKOR (human {kappa} opioid receptor) (26-versus 180-fold). The Ki values for a number of opioid ligands were generally higher when determined by competitive displacement binding against [3H][Dmt1]DALDA compared with [3H]DAMGO, with the exception of Dmt1-substituted peptide analogs. All Dmt1 analogs showed much higher affinity for the µ receptor than corresponding Tyr1 analogs. [35S]GTP{gamma}S (guanosine 5'-O -(3-[35S]thio)triphosphate) binding showed that [Dmt1]DALDA and DAMGO are full agonists at hMOR and hDOR but are only partial agonists at hKOR. The very high affinity and selectivity of [3H][Dmt1]DALDA for the µ receptor, together with its very low nonspecific binding (10–15%) and metabolic stability, make [3H][Dmt1]DALDA an ideal radioligand for labeling µ receptors.


Received May 21, 2003; accepted August 22, 2003.

Address correspondence to: Dr. Hazel H. Szeto, Department of Pharmacology, Weill Medical College of Cornell University, 1300 York Ave., New York, NY 10021. E-mail: hhszeto{at}med.cornell.edu




This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
D. A. Thomas, C. Stauffer, K. Zhao, H. Yang, V. K. Sharma, H. H. Szeto, and M. Suthanthiran
Mitochondrial Targeting with Antioxidant Peptide SS-31 Prevents Mitochondrial Depolarization, Reduces Islet Cell Apoptosis, Increases Islet Cell Yield, and Improves Posttransplantation Function
J. Am. Soc. Nephrol., January 1, 2007; 18(1): 213 - 222.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. N. Talbot, H. K. Happe, and L. C. Murrin
{micro} Opioid Receptor Coupling to Gi/o Proteins Increases during Postnatal Development in Rat Brain
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 596 - 602.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. Wang, X. Sun, L. M. Bohn, and W. Sadee
Opioid Receptor Homo- and Heterodimerization in Living Cells by Quantitative Bioluminescence Resonance Energy Transfer
Mol. Pharmacol., June 1, 2005; 67(6): 2173 - 2184.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Zhao, G.-M. Zhao, D. Wu, Y. Soong, A. V. Birk, P. W. Schiller, and H. H. Szeto
Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury
J. Biol. Chem., August 13, 2004; 279(33): 34682 - 34690.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.